- Home
- PMEC vs MAIA Comparison
PMEC vs MAIA Comparison
Compare PMEC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | MAIA |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 44.9M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PMEC | MAIA |
|---|---|---|
| Price | $1.09 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 192.6K | ★ 446.4K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,349,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $0.54 | $0.87 |
| 52 Week High | $2.44 | $2.74 |
Technical Indicators
Market Signals| Indicator | PMEC | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 51.79 |
| Support Level | $0.97 | $1.07 |
| Resistance Level | $1.10 | $1.25 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 72.43 | 50.85 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.